<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139541">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895582</url>
  </required_header>
  <id_info>
    <org_study_id>P110131</org_study_id>
    <secondary_id>2012-A00326-37</secondary_id>
    <nct_id>NCT01895582</nct_id>
  </id_info>
  <brief_title>Performance of IGRAs for TB Infection Diagnosis in Elderly</brief_title>
  <acronym>IGRage</acronym>
  <official_title>Mycobacterium Tuberculosis Infection Diagnosis in Patients Above 75 Years Old/ Performance of Interferon Gamma Releasing Assays (IGRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Diagnosis and screening for latent tuberculosis in old patients is of special
      interest in regards of the morbidity-mortality of this disease in that context.

      TB-infection diagnosis based on immunological memory detection can be impaired with age. New
      blood tests (QFTB-G and T-SPOT.TB) specific for MTB infection have not been evaluated in
      those old patients.The primary endpoint of this study is the evaluation of the IGRAS for
      active TB diagnosis in patients above 75 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro Interferon Gamma releasing Assay (IGRA) are recommended for LTBI screening as or
      instead of TST, but there accuracy in those old patients are not known: as immune responses
      are impaired in elderly and some of them have already met M tuberculosis before active
      antibiotherapy exists.The aim of this study is to evaluate characteristics of the two
      commercials tests IGRA T-spot-TB® and Quantiferon-TB-gold- in tube® and TST  in old patients
      with or without active Tuberculosis.

      Principal outcome:

      - 3 tests performance for active TB diagnosis in patients older than 75 years-old

      Secondary outcomes :

        -  concordance between IGRAs.

        -  non-concordant results analysis

        -  concordance of IGRAs results with time of TB-infection

        -  biobank

      Methodology :Diagnostic test performance study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of positive, indeterminate, negative tests in each group</measure>
    <time_frame>month27</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test results in clinical LTBI patients</measure>
    <time_frame>month 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with TB-infection date</measure>
    <time_frame>month 27</time_frame>
    <safety_issue>No</safety_issue>
    <description>Test results (positive/negative) according to LTBI date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples collection in order to test new hypothesis in patients with non-concordant results</measure>
    <time_frame>month 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance comparison between tests (T-SPOT.TB®, Quantiferon-Gold-IT®)</measure>
    <time_frame>month 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Ageing</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Active TB-infected patients</arm_group_label>
    <description>TB-infected patients with bacteriological and histological evidences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non active TB-infected patients (already met TB)</arm_group_label>
    <description>some of elders have already met M tuberculosis before active antibiotherapy exists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non active TB-infected patients (other diagnosis)</arm_group_label>
    <description>same symptoms than two others groups but an other diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)
1 blood dry tube  (5ml)</description>
    <arm_group_label>Active TB-infected patients</arm_group_label>
    <arm_group_label>Non active TB-infected patients (already met TB)</arm_group_label>
    <arm_group_label>Non active TB-infected patients (other diagnosis)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected tuberculosis disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 75 years, birth before 1935

          -  Consent signed

          -  Inpatient

          -  Suspicion of active Tuberculosis :

               -  1st Phase (till recruitment of 80 patients in the group 2) : all patient tested
                  for active TB performed

               -  Second Phase (after 1st phase) : all patient treated for active TB

          -  French social right

        Exclusion Criteria:

          -  Tuberculosis disease treatment since 7 days

          -  No 3 months follow-up possible

          -  Immunosuppression
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guislaine CARCELAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne BOURGARIT, MD, PhD</last_name>
    <phone>33 (0)3 88 11 67 19</phone>
    <email>anne.bourgarit-durand@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Servive de Médecine Interne (Pr S. Herson)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume BRETON, MD</last_name>
      <phone>33 1 42 16 10 63</phone>
      <email>guillaume.breton@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne, Diabete et Maladies Métaboliques</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BOURGARIT, MD, PhD</last_name>
      <phone>33 (0) 3 88 11 67 19</phone>
      <email>anne.bourgarit-durand@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Anne BOURGARIT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ageing</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Interferon gamma releasing tests</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
